Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

NCT01832727 Oprozomib þ Dex I/II 128 Phase Ib/II, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous

REVEAL was designed as a parallel phase II trial assess- ing PAD (bortezomib, doxorubicin, dexamethasone) and CVD (cyclophosphamide, bortezomib, dexamethasone) for first-line

Clinical outcomes and survival of patients with myeloma and lymphoma enrolled into phase I clinical trials.. The primary objectives of phase 1 trials are typically to assess the

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide

(2016) A Phase I/IIa study of the CD38 antibody MOR202 alone and in combina- tion with pomalidomide or lenalidomide in patients with relapsed or refractory multiple myeloma.

Eligible patients aged 18 years or older with ECOG performance status 0–2 with relapsed or refractory (duration of first composite complete remission ≤6 months) FLT3-ITD acute

Secondary endpoints were proportion of patients with very good partial response or better; proportion of patients with complete response or better (ie, complete response